Publications (22) Publications de Julen Rodríguez Castejón

2024

  1. Gene therapy with lipid nanoparticles for Fabry disease: Leveraging E-selectin for targeted delivery to endothelial cells

    Journal of Drug Delivery Science and Technology, Vol. 99

  2. Outcomes of Community Pharmacy Interventions on Patients with Medicines Under Additional Monitoring

    INTEGRATED PHARMACY RESEARCH AND PRACTICE, Vol. 13, pp. 115-125

  3. Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems

    BioDrugs, Vol. 38, Núm. 5, pp. 657-680

  4. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review

    Drug Delivery and Translational Research, Vol. 14, Núm. 10, pp. 2615-2628

2023

  1. Expression of a conserved sequence of SARS-CoV-2 for panβ-coronavirus vaccine development

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  2. Modelo SoTL para evaluar el aprendizaje basado en la investigación en el desarrollo de TFG sobre atención farmacéutica

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  3. Nanopartículas lipídicas funcionalizadas con GalNAc para suplementación génica: aplicación en la enfermedad de Fabry

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease

    Pharmaceutics, Vol. 15, Núm. 7

  5. siRNA vectors based on golden lipid nanoparticles for Fabry Disease

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

2022

  1. Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease

    Nanomaterials, Vol. 12, Núm. 14

  2. mRNA delivery technologies: Toward clinical translation

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 207-293

2021

  1. Functionalised SLNs-based nanovectors for gene therapy in Fabry disease: The liver as an α-Galactosidase A factory

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 46-48

  2. Mrna-based nanomedicinal products to address corneal inflammation by interleukin-10 supplementation

    Pharmaceutics, Vol. 13, Núm. 9

  3. Substrate reduction therapy based on siRNA for Fabry Disease

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 84-86

  4. α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice

    Pharmaceutics, Vol. 13, Núm. 6

2020

  1. Gene Therapy

    Advances in Biochemical Engineering/Biotechnology (Springer), pp. 321-368

  2. Nanomedicines to deliver mRNA: State of the art and future perspectives

    Nanomaterials, Vol. 10, Núm. 2

  3. Nucleic Acid Delivery by Solid Lipid Nanoparticles Containing Switchable Lipids: Plasmid DNA vs. Messenger RNA

    Molecules (Basel, Switzerland), Vol. 25, Núm. 24

  4. Nuevo servicio de seguridad y uso de medicamentos sujetos a seguimiento adicional (SSUM) en farmacia comunitaria: resultados iniciales = Jarraipen gehigarria behar duten sendagaien segurtasuna eta erabilera ebaluatzeko zerbitzu berria (SSUM) farmazia komunitarioan: hasierako emaitzak

    Congreso Nacional de Farmacéuticos Comunitarios (9º. 2020). Reunión Internacional de Farmacéuticos Comunitarios (2º. 2020)

  5. Nuevo servicio de seguridad y uso de medicamentos sujetos a seguimiento adicional (ssum) en farmacia comunitaria: resultados iniciales

    Congreso Nacional de Farmacéuticos Comunitarios (9º. Bilbao. 2020)